BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

ROIV

Roivant Sciences Ltd.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Mar

Revenue, quarterly

$1M−33.5% year on year
$30M$20M$10M$0
Q2 ’22Q2 ’23Q2 ’24Q1 ’25Q1 ’26
Company filings · 10-Q filed 6 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$1.25B+0.8% year on year
$7.5B$5B$2.5B$0
Q2 ’22Q2 ’23Q2 ’24Q1 ’25Q1 ’26
Company filings · 10-Q filed 6 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$821M
$500M$0−$500M−$1B
Q2 ’23Q1 ’24Q4 ’24Q2 ’25Q1 ’26
Company filings · 10-Q filed 6 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty